Furthermore, when the ESCC patients were stratified according to clinical stage, the survival rates of patients with SLC39A6 overexpression cancer were significantly lower than those of patients with SLC39A6 down-expression in early stage ESCC (P = 0.036, Fig. 4c). Here, SLC39A6 is linked to cancer.